AstraZeneca PLC
Open
SectorHealthcare
160.1 0.34
Overview
Share price change
24h
Min
157.81
Max
161.41
Income | -1.4B 2.5B |
|---|---|
Sales | 96M 15B |
P/E Sector Avg | 24.32 56.597 |
EPS | 2.63 |
Dividend yield | 1.96 |
Profit margin | 16.095 |
Employees | 96,100 |
EBITDA | -510M 5.2B |
Dividend yield Sector Avg | 1.96% 2.18% |
|---|---|
Next Earnings | 30 Oct 2026 |
Market Cap | -9.6B 252B |
|---|---|
Previous open | 159.76 |
Previous close | 160.1 |
News Sentiment
By Acuity
31%
69%
79 / 339 Healthcare
AstraZeneca PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AstraZeneca PLC Forecast
Sentiment
By Acuity
79 / 339 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.